Page 128 - Eceptor News Today

A recent research paper posted to the bioRxiv* preprint server demonstrated that a cocktail of two synergetic antibodies extensively neutralized severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants, including Omicron BA.1 and BA.2.

In a recent study published in the journal Cell, researchers analyzed the association between human longevity to growth and metabolic pathways.

Researchers investigated the complement component 1q (C1q) binding and subsequent complement activation by neutralizing antibodies (nAbs) produced following COVID-19 vaccination.

Studying mice, scientists at Washington University School of Medicine in St. Louis have identified a neural circuit and a neuropeptide -; a chemical messenger that carries signals between nerve cells -; that transmit the sensation known as pleasant touch from the skin to the brain.

A recent study demonstrated that the phytochemical curcumin is a potent therapeutic prospect against the SARS-CoV-2 Omicron variant

In a new study, researchers described their self-designed chimeric receptor-binding domain-dimer vaccine approach to adapt SARS-CoV-2 variants of concern and variants of interest.

Researchers produced artificial circular ribonucleic acid sponges in a permuted intron-exon system and showed that these did not activate innate immunity.

A recent study published in the journal Immunology analyzed whether sex mattered in the immune response to SARS-CoV-2.

A recent article published in the Med journal reported that the SARS-CoV-2 booster vaccinations enhance the SARS-CoV-2 Omicron sublineage neutralizations.

Researchers identified a human monoclonal antibody (mAb), 87G7, with in vitro neutralizing activity against several SARS-CoV-2 VOCs, including Alpha, Beta, Gamma, Delta, and Omicron.